Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007746.pdf
0001179110-20-007746.rtf
0001179110-20-007746.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007715.pdf
0001179110-20-007715.rtf
0001179110-20-007715.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007717.pdf
0001179110-20-007717.rtf
0001179110-20-007717.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007716.pdf
0001179110-20-007716.rtf
0001179110-20-007716.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007718.pdf
0001179110-20-007718.rtf
0001179110-20-007718.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007721.pdf
0001179110-20-007721.rtf
0001179110-20-007721.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007719.pdf
0001179110-20-007719.rtf
0001179110-20-007719.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007720.pdf
0001179110-20-007720.rtf
0001179110-20-007720.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007722.pdf
0001179110-20-007722.rtf
0001179110-20-007722.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007723.pdf
0001179110-20-007723.rtf
0001179110-20-007723.xls